...
首页> 外文期刊>Oncology >New Developments in the Adjuvant Therapy of Stage II Colon Cancer Risk Assessments in the Older Patient
【24h】

New Developments in the Adjuvant Therapy of Stage II Colon Cancer Risk Assessments in the Older Patient

机译:老年患者II期结肠癌风险评估辅助治疗的新进展

获取原文
获取原文并翻译 | 示例

摘要

While adjuvant chemotherapy has proven benefit in stage III colon cancer, its role for stage II colon cancer remains unclear. This article reviews data regarding adjuvant therapy in stage II colon cancer. We will discuss factors to consider in assessing the risk of recurrence in stage II disease. We will also outline considerations regarding adjuvant therapy in older patients.Colon cancer is estimated to have accounted for 106,100 new cancer cases and 49,920 cancer-related deaths in 2009.[1] Over half of these new diagnoses and deaths occur in individuals age 70 and older. [2] The probability of developing colon cancer increases with advancing age from less than 1 % in the first 4 decades of life to nearly 5% in the seventh decade of life [2]. Nearly 40% of these older individuals are diagnosed with stage II disease [2]. While the overall 5-year survival rate for individuals 75 and older is 67% for all stages of colon cancer, survival of those aged 70 to 79 diagnosed with stage II (T3 or T4, NO, M0) colon cancer is 77% (low-grade disease) or 70% (high-grade disease).
机译:虽然辅助化疗已被证明对III期结肠癌有益处,但对于II期结肠癌的作用仍不清楚。本文回顾了有关II期结肠癌辅助治疗的数据。我们将讨论在评估II期疾病复发风险时应考虑的因素。我们还将概述有关老年患者辅助治疗的注意事项。2009年,结肠癌估计占106,100例新癌症病例和49,920例与癌症相关的死亡。[1]这些新诊断和死亡的一半以上发生在70岁以上的人中。 [2]随着年龄的增长,罹患结肠癌的可能性从生命的前四十年的不到1%增加到生命的第七十年的近5%[2]。这些老年人中将近40%被诊断为II期疾病[2]。虽然75岁及以上个体的5年总生存率在所有阶段的结肠癌中为67%,但诊断为II期(T3或T4,NO,M0)结肠癌的70至79岁人群的生存率为77%(低级疾病)或70%(高级疾病)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号